Login to Your Account



In The Clinic NEWS

The FDA placed a partial clinical hold on trials of CTI Biopharma Corp.'s lead candidate, pacritinib, citing fatal and life-threatening safety issues in patients treated with the drug vs. those provided best available therapy other than JAK inhibitors in the control arm of PERSIST-1, a phase III study of primary myelofibrosis (MF).

With a possible fix for compliance and side-effect issues in Alzheimer's disease, Corium International Inc. drew attention from Wall Street by way of positive top-line phase I data.

Differences in dosing, duration and the disability of patients likely led to Pfizer Inc.'s phase II fizzle with its 5-hydroxytryptamine6 serotonin receptor antagonist in Alzheimer's disease.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: